Electro-Optical Sciences anounced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for MelaFind.
Biogen Idec, Electro-Optical Among “5 Stocks Approaching Greatness”
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.
Clarient Stock Deal Frees Up Cash for Safeguard Scientifics
Safeguard Scientifics Inc. has received $19.5 million in cash, and freed up another $12.3 million in cash due to one of its portfolio companies completing the second part of a private placement of convertible preferred stock.
TargetScan Touch Proven Effective in Duke Study
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
Focal Drug Delivery Helps Deadly Brain Tumor, Study Shows
A method of delivering chemotherapy drugs into a deadly type of brain tumor extended the lives of patients in early clinical trials.
Clarient Launches New Breast Cancer Test
Clarient is launching a new breast cancer test that helps physicians assess the probability of a patient’s cancer returning.
Studies Back Gen-Probe’s Prostate Cancer Test
Eight studies presented this week at the American Urological Association Annual Meeting suggest that Gen-Probe’s investigational test for the prostate cancer gene PCA3 may address some of the major challenges faced by urologists when diagnosing the disease.
Two Studies Cast Doubt On Common Prostate Cancer Test
A common prostate-cancer screening test may be largely ineffective, according to two new studies. Scientists in the U.S. and Europe found that the PSA blood test saves few lives and leads to unnecessary treatments for large numbers of men.
